BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) 10% Owner Jack Bendheim Sells Shares
What Happened
- Jack Bendheim, a 10% owner, director and officer of Phibro Animal Health Corporation (PAHC), sold a total of 22,880 shares in open-market transactions between March 17 and March 19, 2026, generating aggregate proceeds of approximately $1,198,818. Individual reported disposals: 5,280 @ $51.66; 4,311 @ $51.80 (wtd avg); 3,598 @ $53.03 (wtd avg); 2,651 @ $53.64 (wtd avg); 1,939 @ $51.78; 4,977 @ $52.79; and 124 @ $53.24.
Key Details
- Transaction type: Sales (Code S) in open market.
- Dates: March 17–19, 2026. Filing date: March 19, 2026 (appears timely).
- Total shares sold: 22,880; total proceeds: ~$1.20 million.
- Reported prices are weighted averages for several lots; per-footnote price ranges across the trades were roughly $51.19 to $53.88.
- Footnotes: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on Dec 11, 2025 (F1). Many shares are held directly by BFI; Bendheim exercises voting/dispositive power over BFI and disclaims beneficial ownership except for his pecuniary interest (F3). One lot is reported as directly held by Jack Bendheim (F9). Per the filing, detailed per-price breakdowns are available on request (F2–F8).
- Shares owned after transaction: Not specified in the provided data.
Context
- These are routine sales under a pre-established 10b5-1 plan rather than open-market discretionary trades by the insider. For retail investors, sales under 10b5-1 plans often reflect pre-planned liquidity rather than a contemporaneous view on the company’s prospects; purchases generally carry more inferred bullish signal. No options were exercised and no awards or gifts were reported in this filing.
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-03-17$51.66/sh−5,280$272,760→ 90,920 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-03-18$51.80/sh−4,311$223,301→ 86,609 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-03-18$53.03/sh−3,598$190,819→ 83,011 total(indirect: See) - Sale
Class A Common Stock
[F1][F6][F3]2026-03-18$53.64/sh−2,651$142,209→ 80,360 total(indirect: See) - Sale
Class A Common Stock
[F1][F7][F3]2026-03-19$51.78/sh−1,939$100,409→ 78,421 total(indirect: See) - Sale
Class A Common Stock
[F1][F8][F3]2026-03-19$52.79/sh−4,977$262,718→ 73,444 total(indirect: See) - Sale
Class A Common Stock
[F1][F3]2026-03-19$53.24/sh−124$6,602→ 73,320 total(indirect: See)
Holdings
- 16,840
Class A Common Stock
[F9]
Footnotes (9)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.26 to $52.13. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 8.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.29 to $52.21.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $53.295.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.365 to $53.88.
- [F7]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.19 to $52.18.
- [F8]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.195 to $53.125.
- [F9]The reported securities are directly held by Jack Bendheim.